CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.
Fourth Quarter and Fiscal Year End 2011 ResultsPalatin reported a net loss of $3.3 million, or $(0.09) per basic and diluted share, for the quarter ended June 30, 2011, compared to a net loss of $4.2 million, or $(0.40) per basic and diluted share, for the same period in 2010.The change in net loss for the quarter ended June 30, 2011 compared to the net loss for the quarter ended June 30, 2010 was primarily attributable to $1.3 million of non-cash, non-operating income, which represents the decrease in estimated fair value of the warrant liability from March 31, 2011 through May 11, 2011, the date the warrants ceased to be classified as a liability upon stockholder approval of the increase in authorized common stock
Palatin's net loss for the year ended June 30, 2011 was $12.8 million, or $(0.64) per basic and diluted share, compared to a net loss of $1.8 million, or $(0.18) per basic and diluted share, for the year ended June 30, 2010.
The change in net loss for the year ended June 30, 2011 compared to the net loss for the year ended June 30, 2010 was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca as a result of the successful completion of the research collaboration portion of the agreements.
RevenueRevenues in the quarter ended June 30, 2011 were $0.2 million, compared to $0.7 million for the same period in 2010. For the year ended June 30, 2011, revenues were $1.5 million, compared to $14.2 million for year ended June 30, 2010.
Costs and ExpensesFor the quarter ended June 30, 2011, total operating expenses were $4.7 million compared to $4.9 million for the comparable quarter of 2010. For the year ended June 30, 2011, total operating expenses were $15.1 million compared to $17.2 million for the year ended June 30, 2010. The decreases in operating expenses for the respective periods is the result of reducing staffing levels pursuant to Palatin's strategic decision announced in September 2010.
Cash positionPalatin's cash and cash equivalents were $18.9 million as of June 30, 2011, compared to cash, cash equivalents and investments of $8.9 million at June 30, 2010, with current liabilities of $2.8 million as of June 30, 2011 compared to $2.4 million as of June 30, 2010.
Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.
CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on September 22, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-800-281-7970 (domestic) or 1-913-312-0671 (international), pass code 9488233. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 9488233. The webcast and telephone replay will be available through September 29, 2011.
About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.
Forward-looking Statements Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release. PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statement of Operations(unaudited)Quarter Ended June 30, Year Ended June 30,2011201020112010REVENUESLicense and contract
155,840674,9571,475,45714,180,727OPERATING EXPENSES:Research and development
3,217,3853,554,52110,377,01912,293,910General and administrative
1,525,0261,374,3204,751,8244,901,203Total operating expenses
4,742,4114,928,84115,128,84317,195,113Loss from operations
(4,586,571)(4,253,884)(13,653,386)(3,014,386)OTHER INCOME (EXPENSE):Investment income
(4,999)(3,862)(10,606)(13,165)Decrease/(increase) in fair value of warrants
1,255,425-(2,266)-Gain on sale of securities
--119,346-Gain/(loss) on disposition of supplies and equipment
--(5,666)95,000Total other income, net
1,277,34217,503200,066223,470Loss before income taxes
(3,309,229)(4,236,381)(13,453,320)(2,790,916)Income tax benefit
$ (3,309,229)$ (4,236,381)$(12,815,929)$ (1,792,508)Basic and diluted net loss per common share
(0.18)Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share
34,900,59110,722,06120,084,0229,861,215PALATIN TECHNOLOGIES, INC.
and SubsidiaryConsolidated Balance Sheets(unaudited)June 30, 2011June 30, 2010ASSETSCurrent assets: Cash and cash equivalents$
5,405,430 Available-for-sale investments-3,462,189 Accounts receivable131,1492,879 Prepaid expenses and other current assets261,947393,313Total current assets19,262,7359,263,811Property and equipment, net1,305,3312,388,365Restricted cash350,000475,000Other assets254,787261,701Total assets$
2,388,877LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities: Capital lease obligations$
9,670 Accounts payable 496,908155,795 Accrued expenses1,854,0072,219,466 Accrued expenses374,094- Unearned revenue46,105-Total current liabilities2,806,0372,394,931Capital lease obligations 42,18614,284Deferred rent132,855661,389Total liabilities2,981,0783,070,604Stockholders' equity: Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,997 shares as of June 30, 2011 and 2010, respectively5050 Common stock of $0.01 par value – authorized 100,000,000 shares; issued and outstanding 34,900,591 and 11,702,818 shares as of June 30, 2011 and 2010, respectively349,006117,028 Additional paid-in capital239,832,826218,236,723 Accumulated other comprehensive income-138,650 Accumulated deficit (221,990,107)(209,174,178)Total stockholders' equity18,191,7759,318,273Total liabilities and stockholders' equity$
|SOURCE Palatin Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved